Welcome to our dedicated page for BioAtla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on BioAtla stock.
BioAtla, Inc. (NASDAQ: BCAB) is a clinical-stage biopharmaceutical company committed to advancing the treatment of cancer through its innovative protein therapeutic products. Headquartered in San Diego, California, with a strategic presence in Beijing, China, BioAtla leverages its proprietary Conditionally Active Biologics (CAB) technology to develop novel monoclonal and bispecific antibodies.
The core of BioAtla's work lies in the engineering of antibodies that become active under the unique conditions of the tumor microenvironment, thus improving tumor selectivity and reducing on-target toxicity. This technology aims to enhance the therapeutic index of drug candidates, ultimately providing safer and more effective cancer treatments.
BioAtla's pipeline includes several promising candidates. Mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021) are in Phase 2 clinical testing, targeting AXL and ROR2 respectively. Another key asset, evalstotug (BA3071), is a CTLA-4 inhibitor designed to minimize systemic toxicity and facilitate safer combination therapies with anti-PD-1 antibodies. Furthermore, the company's first bispecific T-cell engager antibody, BA3182, is undergoing Phase 1 trials, focusing on EpCAM and engaging CD3 expressing T cells.
BioAtla has an extensive patent portfolio, with over 750 patents filed, more than 475 of which have been granted. This robust intellectual property coverage supports the company's competitive edge in the biotechnology sector.
Recent updates include the initiation of a Phase 1 clinical trial for BA3361, a next-generation CAB-Nectin4-ADC, which demonstrated superior activity in pancreatic cancer models. The company also continues to build strategic partnerships and collaborations to advance its research and commercialize its products effectively.
For further information and the latest updates, visit BioAtla's official website or contact their investor relations team.
BioAtla, Inc. (Nasdaq: BCAB) reported progress in its clinical trials and financial results for Q4 and full-year 2022. The company has cleared dose-limiting toxicity (DLT) observation periods for its CAB-AXL therapy (BA3011) in multiple studies, with significant readouts expected in the second half of 2023. Cash reserves stood at $215.5 million, sufficient for operations into 2025. However, the net loss increased to $106.5 million for 2022. BioAtla anticipates several milestones, including FDA interactions and the initiation of several Phase 2 trials, demonstrating a strong commitment to advancing its product candidates aimed at high unmet medical needs.
BioAtla, a clinical-stage biotechnology company, will host a conference call on March 23, 2023, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ending December 31, 2022. The company specializes in Conditionally Active Biologic (CAB) therapeutics aimed at treating solid tumors. This presentation will provide key business highlights and insights into its clinical programs, including two CAB candidates in Phase 2 trials.
Investors can access the results prior to the call on the company's website.
BioAtla, Inc. (Nasdaq: BCAB) announced the departure of President Scott Smith, who will become the CEO of Viatris. Smith, who joined BioAtla in 2018, will remain connected to the company as a Board member. The company expressed gratitude for his contributions, emphasizing his role in expanding operations and advancing clinical programs. BioAtla continues to develop its Conditionally Active Biologic (CAB) technology, applicable for solid tumors, and has two CAB programs in Phase 2 clinical testing. The company holds extensive patent coverage for its CAB technology with 704 patents worldwide.
BioAtla, Inc. (Nasdaq: BCAB) announced FDA clearance for its IND application to initiate a Phase 1 clinical study of BA3182, a bispecific T-cell engager targeting advanced adenocarcinoma. This innovative therapy addresses common adenocarcinoma types, including lung, breast, and prostate cancers. BA3182 shows significant therapeutic potential due to its high specificity binding under acidic tumor conditions, aiming to improve patient outcomes while minimizing toxicity. The company projects sufficient cash reserves to support operations into 2025 as they pursue critical milestones in this promising clinical program.
BioAtla, Inc. (Nasdaq: BCAB) announced encouraging interim results of Mecbotamab vedotin (BA3011) in a Phase 2 trial for PD-1 refractory non-small cell lung cancer (NSCLC), with a total of 29 patients enrolled. The company is set to initiate the Phase 2 part 2 study for Undifferentiated Pleomorphic Sarcoma (UPS) and continues to progress in the Phase 1 study of BA3071. BioAtla expects multiple significant milestones throughout 2023 and has a cash runway extending into 2025 to support its clinical programs.
Viatris Inc. (NASDAQ: VTRS) has appointed Scott A. Smith and Elisha W. Finney to its board of directors, succeeding retiring members Neil Dimick and Ian Read. Scott Smith, formerly President at Celgene, brings extensive experience in the biotechnology sector, while Finney has a strong financial background from her tenure at Varian Medical Systems. Both new directors are expected to enhance Viatris' strategy for growth and innovation in the pharmaceutical sector. The changes come as the company prepares to advance to its second phase post-Combination in November 2020.
BioAtla, a clinical-stage biotechnology company, announced its participation in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2023. The company will host a fireside chat and conduct one-on-one investor meetings on January 10, 2023, at 3:00 p.m. PST. BioAtla focuses on developing Conditionally Active Biologic (CAB) therapeutics for solid tumors. The firm boasts extensive patent coverage and currently has two first-in-class CAB programs in Phase 2 clinical testing, targeting AXL and ROR2.
BioAtla, Inc. (Nasdaq: BCAB) announced participation in the upcoming Jefferies London Healthcare Conference, taking place November 15-17, 2022. Scott Smith, President, and Sheri Lydick, Senior VP of Commercial Strategy, will engage in a fireside chat and one-on-one investor meetings on November 17, 2022, at 9:45 a.m. GMT. This event highlights BioAtla's innovation in Conditionally Active Biologic (CAB) antibody therapeutics aimed at treating solid tumors. The company boasts over 600 patents and is currently advancing two CAB programs in Phase 2 clinical testing, targeting AXL and ROR2.
FAQ
What is the current stock price of BioAtla (BCAB)?
What is the market cap of BioAtla (BCAB)?
What is BioAtla, Inc. known for?
Where are BioAtla's main operations located?
What are BioAtla's leading drug candidates?
What is CAB technology?
How extensive is BioAtla's patent portfolio?
What recent developments has BioAtla announced?
Who can I contact for more information about BioAtla?
What types of cancers are BioAtla's treatments targeting?
What are the benefits of BioAtla's CAB technology?